Icahn Is Forest’s Latest Wolf At The Door
Specialty pharma Forest Pharmaceuticals Inc. has already spent months fending off doubts about the future of its pipeline as well as a potential federal ban prohibiting its long-time CEO from negotiating federal contracts. Now, the company has a new wolf at the door: dissident investor Carl Icahn.
You may also be interested in...
Amid drama from dissident investor Carl Icahn, Forest is relieved of the fear that the federal OIG could bar its CEO from contracting with government health care programs.
The specialty pharma countered the activist investor's June challenge with its own nominees, while defending its diversification strategy.
The future of Burt’s Bees marketer Clorox is unclear with a buyout offer on the table from its largest shareholder.